ClinicalTrials.gg
TerminatedNCT03637764Updated Jul 10, 2023Results posted

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

A Phase 1/2 interventional study of Isatuximab SAR650984 and Atezolizumab in Neoplasm, sponsored by Sanofi. Terminated at 26 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-10.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study was stopped after interim analysis for 4 cohorts (HCC, SCCHN, EOC, and GBM) indicated that the results did not fulfill the preplanned interim analysis criteria to move to Phase 2 stage 2 in all 4 cohorts.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary Objectives:

  • Phase 1: To characterize the safety and tolerability of isatuximab in combination with atezolizumab in participants with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC), or recurrent glioblastoma multiforme (GBM), and to determine the recommended Phase 2 dose (RP2D).
  • Phase 2: To assess response rate (RR) of isatuximab in combination with atezolizumab in participants with HCC or SCCHN or EOC.
  • Phase 2: To assess the progression free survival rate at 6 months (PFS-6) of isatuximab in combination with atezolizumab, or as a single agent in participants with GBM.

Secondary Objectives:

  • To evaluate the safety profile of isatuximab monotherapy (GBM only), or in combination with atezolizumab in Phase 2.
  • To evaluate the immunogenicity of isatuximab and atezolizumab.
  • To characterize the pharmacokinetic (PK) profile of isatuximab single agent (GBM only) and atezolizumab in combination with isatuximab.
  • To assess the overall efficacy of isatuximab in combination with atezolizumab, or single agent (GBM only).
Read the detailed description

The total study duration per participant was up to 28 months including up to 28 days screening period, up to 24 months treatment period, and a 3 month safety follow up period.

02

Conditions studied

  • Neoplasm

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 107 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a known diagnosis of either unresectable HCC, platinum- recurrent/ SCCHN, platinum-resistant/refractory EOC with evidence of or recurrent GBM.
  • Greater than or equal to (>=)18 years of age.
  • For participants with HCC: Documentation of progressive disease (PD) during or after treatment with either sorafenib or lenvatinib, or intolerance to the therapy.
  • For participants with SCCHN: Received and failed up to 2 lines of prior systemic anti-cancer therapy with documentation of tumor recurrence or PD within 6 months of last platinum-based therapy in primary, recurrent, or metastatic setting.
  • For participants with EOC: Received up to 3 lines of prior platinum-containing therapy when the disease was platinum-sensitive, and the participants should not have received any systemic therapy for platinum-resistant/refractory disease. Specific to France only: Documentation of PD on or after 1 line of anti-cancer therapy for platinum resistant/refractory disease (unless participants are ineligible or intolerant to standard of care for platinum-resistant/refractory disease).
  • For participants with GBM: Documentation of PD or first recurrence during or after temozolomide maintenance therapy for newly diagnosed GBM treated with radiotherapy plus concurrent temozolomide.

Exclusion criteria

Exclusion criteria:

  • Prior exposure to agent that blocks CD38 or participation in clinical studies with isatuximab.
  • For participants with HCC, SCCHN, EOC or GBM prior exposure to any agent (approved or ) that blocks the /PD-L1 pathway.
  • Evidence of other immune related disease /conditions.
  • History of non-infectious pneumonitis requiring or current pneumonitis; history of the thoracic radiation.
  • Received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
  • Prior solid organ or bone marrow transplantation.
  • performance status >=2 for participants with HCC, SCCHN or EOC or performance score less than or equal to (\<=) 70 for participants with GBM.
  • Poor bone marrow reserve.
  • Poor organ function.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Cohort A: HCC: Isatuximab + Atezolizumab

    Participants with hepatocellular carcinoma (HCC) received atezolizumab 1200 milligrams, every 3 weeks (Q3W), intravenous (IV) infusion along with isatuximab 10 milligrams per kilogram (mg/kg), IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable adverse events (AE), participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 106 weeks).

    Drug: Isatuximab SAR650984 · Drug: Atezolizumab

  • Experimental
    Cohort B: SCCHN: Isatuximab + Atezolizumab

    Participants with squamous cell carcinoma of the head and neck (SCCHN) received atezolizumab 1200 milligrams,Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 108 weeks).

    Drug: Isatuximab SAR650984 · Drug: Atezolizumab

  • Experimental
    Cohort C: EOC: Isatuximab + Atezolizumab

    Participants with epithelial ovarian cancer (EOC) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 61 weeks).

    Drug: Isatuximab SAR650984 · Drug: Atezolizumab

  • Experimental
    Cohort D-1: GBM: Isatuximab + Atezolizumab

    Participants with glioblastoma multiforme (GBM) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks).

    Drug: Isatuximab SAR650984 · Drug: Atezolizumab

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Tecentriq®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLTs: AEs occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause which included: hematological abnormalities: Grade(G) 4 neutropenia(N) for 7 or more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 thrombocytopenia with clinically significant bleeding/ G4 thrombocytopenia. Non-hematological abnormalities: G \>=2 Aspartate transaminase (AST)/ Alanine transaminase (ALT) elevation simultaneous with G \>=2 total bilirubin elevation without initial findings of cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting greater than (\>)3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that study committee deemed to be dose-limiting, regardless of grade, was also considered DLT.

    Time frame: Cycle 1 (21 days)

  2. Recommended Phase 2 Dose (RP2D)

    RP2D was the starting dose selected for Phase 2 part of the study. RP2D was the selected dose at which no more than 1 out of 6 participants (starting dose or dose level minus -1 \[DL-1\]) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: Adverse Event (AE) occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7/ more consecutive days, G3 to G4 N with fever, G3/G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE.

    Time frame: Cycle 1 (21 days)

  3. Maximum Tolerated Dose (MTD)

    MTD was defined as the highest dose level at which no more than 1 out of 6 participants (starting dose or DL-1) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: AE occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7 or more consecutive days, G3 to G4 N with fever, G3 or G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities or AEs.

    Time frame: Cycle 1 (21 days)

  4. Percentage of Participants With Overall Response (OR): For HCC/SCCHN/EOC Cohorts

    OR was defined as the percentage of participants with complete response (CR) and partial response (PR) as best overall response, assessed per RECIST 1.1 criteria. Best overall response was derived per RECIST 1.1 criteria using disease assessments performed from the first dose of treatment throughout the study excluding any assessments performed after the cut-off date or following the initiation of a further anticancer treatment. CR was defined as the disappearance of all target lesions, pathological lymph nodes (target/non-target)- reduction in short axis \<10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Disease progression was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum, sum with an absolute increase of diameter of at least 5 mm and appearance of \>1 new lesion.

    Time frame: From randomization until disease progression, or death or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)

  5. Probability of Participants With Progression Free Survival at 6 Months (PFS-6): GBM Cohort

    PFS-6 was defined as the probability of participants alive without disease progression at 6 months as assessed by RANO criteria. Participants who didn't experience documented progression or death before analysis cut-off date or date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. Per RANO criteria, progressive disease was defined as \>=25% increase size of T1- gadolinium enhancing disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status. PFS-6 was evaluated by Kaplan-Meier method.

    Time frame: From randomization until 6 months after the last participant's first treatment in the GBM Cohort D-1

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment).

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

  7. Number of Participants With Hematological Abnormalities

    Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased, and neutrophil count decreased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

  8. Number of Participants With Abnormal Electrolyte Parameters

    Electrolyte parameters assessed were hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia, hypoglycemia and hyperglycemia. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

  9. Number of Participants With Renal Function Abnormalities

    Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

  10. Number of Participants With Liver Abnormalities

    Abnormal liver function parameters assessed were AST increased, ALT increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

Secondary outcomes

  1. Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab

    ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure:106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

  2. Number of Participants With Anti-drug Antibodies (ADA) Response Against Atezolizumab

    ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

    Time frame: From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)

  3. Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab

    Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At start of infusion (SOI), end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  4. Pharmacokinetics (PK): Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab

    Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

    Time frame: At end of infusion on Cycle 1 Day 1

  5. Pharmacokinetics (PK): Time to Reach Cmax (Tmax) After First Infusion of Isatuximab

    Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  6. Pharmacokinetics (PK): Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab

    Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  7. Pharmacokinetics (PK): Time of Clast (Tlast) After First Infusion of Isatuximab

    Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  8. Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) After First Infusion of Isatuximab

    AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  9. Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-168h) After First Infusion of Isatuximab

    AUC0-168h was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using non-compartmental analysis after first infusion of isatuximab.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

  10. Pharmacokinetics (PK): Trough Plasma Concentrations (Ctrough) of Isatuximab

    Ctrough was the plasma concentration of isatuximab observed just before treatment administration during repeated dosing.

    Time frame: Pre-infusion on Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 1 Day 15

  11. Plasma Concentration of Atezolizumab

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1 and Cycle 16 Day 1

  12. Best Percent Change From Baseline in Tumor Burden

    Best tumor burden change was defined as the best percent-change from baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.

    Time frame: From randomization until progression or death or study cut-off date whichever occurred first (maximum duration of exposure: up to 108 weeks)

  13. Percentage of Participants With Disease Control (DC) >=6 Months

    DC: percentage of participants with complete response (CR), partial response (PR) \& stable disease (SD) rate. RANO criteria, CR: no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable/ reduced (red) T2/FLAIR signal, no new lesion (NL), no corticosteroid use (CU) \& stable/ red clinical status (CS); PR: \>=50% change in size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/ red CU \& stable/ improved CS (ICS). SD: \<50% reduction to \<25% increase (inc) size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/red CU \& stable/ICS. Progressive disease (PD): \>=25% inc size of T1-Gd+ disease/ inc T2/FLAIR signal/ presence of NL/ worsening CS. RECIST criteria: CR: Disappearance of target lesions. Reduction in short axis to \<10 mm of lymph nodes; PR: 30% decrease in sum of diameters of target lesions; PD: 20% inc in sum of diameters of target lesions; SD: Neither sufficient shrinkage from baseline study to qualify for PR nor sufficient inc to qualify for PD.

    Time frame: From the date of first response to disease progression or death, or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)

  14. Duration of Response (DOR)

    Time from date of 1st response until date of first documented recurrent/progressive disease (PD) or death whichever occurred 1st. In absence of disease progression or death before analysis cut-off date or date of initiation of further anticancer treatment, DOR was censored at date of last valid response. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1, CR: disappearance of all target lesions; PR: at least 30% decrease in sum of diameters of target lesions, PD: at least 20% increase in sum of diameters of target lesions. Per RANO criteria; CR: no change in size of T1-Gd+ disease, stable/reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable/improved status; PR: \>=50% change in size of T1-Gd+, stable/reduced T2/FLAIR signal, no new lesion, stable/reduced corticosteroid use, and stable/improved status. PD:\>=25% increase size of T1-Gd+/increased T2/FLAIR signal/presence of new lesion/worsening status.

    Time frame: From the date of first response until disease progression or death, or study cut-off date whichever occurred first (maximum duration of exposure: up to 108 weeks)

  15. Progression-free Survival (PFS)

    PFS was defined as time (in months) from 1st study treatment administration to date of 1st documented radiographic progression or date of death from any cause, whichever was 1st. Participants who didn't experience progression or death before analysis cut-off date/date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1 criteria, PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study. Appearance of 1 or more new lesions was also considered progression. Per RANO criteria, PD: \>=25% increase in product of perpendicular diameters of any target lesion, or worsening neurologic status not explained by causes unrelated to tumor progression.

    Time frame: From date of first study treatment administration until disease progression or death or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)

  16. Percentage of Participants With Response as Per Response Assessment for Neuro-Oncology (RANO) Criteria: GBM Cohort

    Response rate for participants with GBM was defined as percentage of participants with CR \& PR as best overall response (BOR), assessed by Investigators using RANO criteria. BOR was derived per RANO criteria using disease assessments performed from 1st dose of treatment through study excluding any assessments performed after cut-off date or following initiation of further anticancer treatment. Per RANO criteria; CR was defined as no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; PR was defined as \>=50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status. Progressive disease was defined as \>=25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.

    Time frame: From randomization until progression, or death, or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks for Cohort D-1)

07

Results

Posted Jun 8, 2023
Limitations and caveats
Study was stopped after performance of interim analysis for 4 cohorts (Cohort A \[HCC\], Cohort B \[SCCHN\], Cohort C \[EOC\] \& Cohort D-1 \[GBM\]) as the efficacy results observed in each cohort did not fulfill the pre-planned interim analysis criteria allowing the study to move to Phase 2 Stage 2 in these 4 cohorts.

Participant flow

Study was conducted at 26 active sites in 8 countries. A total of 107 participants were enrolled between 06 August 2018 and 21 July 2020 and received isatuximab in combination with atezolizumab. Study was planned to be conducted in 2 parts: Phase 1 (safety run-in) and Phase 2 (efficacy with a 2-stage design).

Participant flow — Overall Study
MilestoneCohort A: Hepatocellular Carcinoma (HCC): Isatuximab + AtezolizumabCohort B: Squamous Cell Carcinoma of the Head and Neck (SCCHN): Isatuximab + AtezolizumabCohort C: Epithelial Ovarian Cancer (EOC): Isatuximab + AtezolizumabCohort D-1: Glioblastoma Multiforme (GBM): Isatuximab + Atezolizumab
Started27291833
Completed1300
Not completed26261833
Withdrew: Adverse event2001
Withdrew: Progressive disease23231831
Withdrew: Withdrawal by subject1301

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLTs: AEs occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause which included: hematological abnormalities: Grade(G) 4 neutropenia(N) for 7 or more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 thrombocytopenia with clinically significant bleeding/ G4 thrombocytopenia. Non-hematological abnormalities: G \>=2 Aspartate transaminase (AST)/ Alanine transaminase (ALT) elevation simultaneous with G \>=2 total bilirubin elevation without initial findings of cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting greater than (\>)3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that study committee deemed to be dose-limiting, regardless of grade, was also considered DLT.

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsIsatuximab + Atezolizumab
Number of Participants With Dose Limiting Toxicities (DLTs)0
PrimaryRecommended Phase 2 Dose (RP2D)

RP2D was the starting dose selected for Phase 2 part of the study. RP2D was the selected dose at which no more than 1 out of 6 participants (starting dose or dose level minus -1 \[DL-1\]) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: Adverse Event (AE) occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7/ more consecutive days, G3 to G4 N with fever, G3/G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · milligrams per kilogram (mg/kg)
Recommended Phase 2 Dose (RP2D)
milligrams per kilogram (mg/kg)Isatuximab + Atezolizumab
Recommended Phase 2 Dose (RP2D)10
PrimaryMaximum Tolerated Dose (MTD)

MTD was defined as the highest dose level at which no more than 1 out of 6 participants (starting dose or DL-1) or 2 out of 12 participants (starting dose) experienced a DLT related to the investigational medicinal product. DLTs: AE occurring during 1st treatment cycle, unless due to disease progression/obviously unrelated cause included: hematological abnormalities: G4 N for 7 or more consecutive days, G3 to G4 N with fever, G3 or G4 thrombocytopenia. Non-hematological abnormalities: G\>=2 AST/ ALT elevation simultaneous with G \>=2 total bilirubin elevation without cholestasis or any other reason found, G4 non-hematologic AE, G3 to 4 cytokine release syndrome, G3 non-hematological AE lasting \>3 days, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities or AEs.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · mg/kg
Maximum Tolerated Dose (MTD)
mg/kgIsatuximab + Atezolizumab
Maximum Tolerated Dose (MTD)10
PrimaryPercentage of Participants With Overall Response (OR): For HCC/SCCHN/EOC Cohorts

OR was defined as the percentage of participants with complete response (CR) and partial response (PR) as best overall response, assessed per RECIST 1.1 criteria. Best overall response was derived per RECIST 1.1 criteria using disease assessments performed from the first dose of treatment throughout the study excluding any assessments performed after the cut-off date or following the initiation of a further anticancer treatment. CR was defined as the disappearance of all target lesions, pathological lymph nodes (target/non-target)- reduction in short axis \<10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Disease progression was defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum, sum with an absolute increase of diameter of at least 5 mm and appearance of \>1 new lesion.

Time frame:
From randomization until disease progression, or death or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response (OR): For HCC/SCCHN/EOC Cohorts
percentage of participantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + Atezolizumab
Percentage of Participants With Overall Response (OR): For HCC/SCCHN/EOC Cohorts7.4 (1.3 to 21.5)13.8 (4.9 to 28.8)5.6 (0.3 to 23.8)
PrimaryProbability of Participants With Progression Free Survival at 6 Months (PFS-6): GBM Cohort

PFS-6 was defined as the probability of participants alive without disease progression at 6 months as assessed by RANO criteria. Participants who didn't experience documented progression or death before analysis cut-off date or date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. Per RANO criteria, progressive disease was defined as \>=25% increase size of T1- gadolinium enhancing disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status. PFS-6 was evaluated by Kaplan-Meier method.

Time frame:
From randomization until 6 months after the last participant's first treatment in the GBM Cohort D-1
Reported as:
Number · probability of participants
Probability of Participants With Progression Free Survival at 6 Months (PFS-6): GBM Cohort
probability of participantsCohort D-1: GBM: Isatuximab + Atezolizumab
Probability of Participants With Progression Free Survival at 6 Months (PFS-6): GBM Cohort0.033 (0.002 to 0.145)
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment).

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (TESAEs)
ParticipantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
TEAE26291833
TESAE121689
PrimaryNumber of Participants With Hematological Abnormalities

Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased, and neutrophil count decreased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Count of participants · Participants
Number of Participants With Hematological Abnormalities
ParticipantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Anemia: Grade 1111367
Anemia: Grade 251262
Anemia: Grade 32300
Anemia: Grade 40000
White blood cell decreased: Grade 195412
White blood cell decreased: Grade 22123
White blood cell decreased: Grade 30010
White blood cell decreased: Grade 40000
Platelet count decreased: Grade 1115510
Platelet count decreased: Grade 21000
Platelet count decreased: Grade 31100
Platelet count decreased: Grade 41000
Lymphocyte count decreased: Grade 142210
Lymphocyte count decreased: Grade 2814712
Lymphocyte count decreased: Grade 33743
Lymphocyte count decreased: Grade 40401
Neutrophil count decreased: Grade 13101
Neutrophil count decreased: Grade 20032
Neutrophil count decreased: Grade 30000
Neutrophil count decreased: Grade 40000
PrimaryNumber of Participants With Abnormal Electrolyte Parameters

Electrolyte parameters assessed were hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia, hypoglycemia and hyperglycemia. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrolyte Parameters
ParticipantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Hyponatremia: Grade 191284
Hyponatremia: Grade 20000
Hyponatremia: Grade 31401
Hyponatremia: Grade 40000
Hypokalemia: Grade 12544
Hypokalemia: Grade 20000
Hypokalemia: Grade 30200
Hypokalemia: Grade 40000
Hyperkalemia: Grade 15622
Hyperkalemia: Grade 21011
Hyperkalemia: Grade 30000
Hyperkalemia: Grade 40000
Hypocalcemia: Grade 19729
Hypocalcemia: Grade 20000
Hypocalcemia: Grade 30000
Hypocalcemia: Grade 40000
Hypercalcemia: Grade 11500
Hypercalcemia: Grade 20200
Hypercalcemia: Grade 31200
Hypercalcemia: Grade 40100
Hypoalbuminemia: Grade 19772
Hypoalbuminemia: Grade 21311
Hypoalbuminemia: Grade 30200
Hypoalbuminemia: Grade 40000
Hypoglycemia: Grade 11302
Hypoglycemia: Grade 21000
Hypoglycemia: Grade 30000
Hypoglycemia: Grade 40000
Hyperglycemia: Grade 110728
Hyperglycemia: Grade 25620
Hyperglycemia: Grade 31002
Hyperglycemia: Grade 40100
Hypernatremia: Grade 10405
Hypernatremia: Grade 20000
Hypernatremia: Grade 30000
Hypernatremia: Grade 40000
PrimaryNumber of Participants With Renal Function Abnormalities

Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Count of participants · Participants
Number of Participants With Renal Function Abnormalities
ParticipantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
CrCl: >=60 - <90 mL/min/1.73m^28131016
CrCl: >=30 - <60mL/min/1.73m^25451
CrCl: >=15 - <30 mL/min/1.73m^23000
CrCl: <15 mL/min/1.73m^20100
Creatinine increased: Grade 122191324
Creatinine increased: Grade 22220
Creatinine increased: Grade 31100
Creatinine increased: Grade 40000
Hyperuricemia: Grade 10000
Hyperuricemia: Grade 20000
Hyperuricemia: Grade 35753
Hyperuricemia: Grade 41110
PrimaryNumber of Participants With Liver Abnormalities

Abnormal liver function parameters assessed were AST increased, ALT increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Count of participants · Participants
Number of Participants With Liver Abnormalities
ParticipantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
AST increased: Grade 114563
AST increased: Grade 25001
AST increased: Grade 33000
AST increased: Grade 41000
ALT increased: Grade 1118611
ALT increased: Grade 24010
ALT increased: Grade 32001
ALT increased: Grade 41000
ALP increased: Grade 1121370
ALP increased: Grade 28230
ALP increased: Grade 32010
ALP increased: Grade 40000
BB increased: Grade 16100
BB increased: Grade 22002
BB increased: Grade 33000
BB increased: Grade 41000
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab

ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure:106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Number · count of participants
Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab
count of participantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Treatment-induced ADA2011
Treatment boosted ADA0000
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) Response Against Atezolizumab

ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

Time frame:
From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1)
Reported as:
Number · count of participants
Number of Participants With Anti-drug Antibodies (ADA) Response Against Atezolizumab
count of participantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Treatment-induced ADA2210
Treatment boosted ADA0000
SecondaryPharmacokinetics (PK): Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab

Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At start of infusion (SOI), end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
micrograms per milliliter (mcg/mL)Cohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab219 ± 50.5218 ± 48.7262 ± 69.7266 ± 66.7
SecondaryPharmacokinetics (PK): Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

Time frame:
At end of infusion on Cycle 1 Day 1
Reported as:
Mean · mcg/mL
Pharmacokinetics (PK): Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab
mcg/mLCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Concentration Observed at the End of Intravenous Infusion (Ceoi) of Isatuximab216 ± 50.8207 ± 54.9251 ± 77.3263 ± 68.8
SecondaryPharmacokinetics (PK): Time to Reach Cmax (Tmax) After First Infusion of Isatuximab

Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Median · hours
Pharmacokinetics (PK): Time to Reach Cmax (Tmax) After First Infusion of Isatuximab
hoursCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Time to Reach Cmax (Tmax) After First Infusion of Isatuximab4.00 (2.42 to 7.92)3.37 (2.08 to 8.95)6.83 (3.00 to 8.83)4.13 (2.65 to 8.38)
SecondaryPharmacokinetics (PK): Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab

Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · mcg/mL
Pharmacokinetics (PK): Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
mcg/mLCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab75.9 ± 35.367.8 ± 20.486.0 ± 22.2103 ± 28.4
SecondaryPharmacokinetics (PK): Time of Clast (Tlast) After First Infusion of Isatuximab

Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Median · hours
Pharmacokinetics (PK): Time of Clast (Tlast) After First Infusion of Isatuximab
hoursCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Time of Clast (Tlast) After First Infusion of Isatuximab166 (75.4 to 191)167 (162 to 192)167 (152 to 212)166 (136 to 192)
SecondaryPharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) After First Infusion of Isatuximab

AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · micrograms*hour/milliliter (mcg*h/mL)
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) After First Infusion of Isatuximab
micrograms*hour/milliliter (mcg*h/mL)Cohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to Last Quantifiable Concentration (AUClast) After First Infusion of Isatuximab20000 ± 457019700 ± 450024400 ± 712026300 ± 6510
SecondaryPharmacokinetics (PK): Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-168h) After First Infusion of Isatuximab

AUC0-168h was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using non-compartmental analysis after first infusion of isatuximab.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Reported as:
Mean · mcg*h/mL
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-168h) After First Infusion of Isatuximab
mcg*h/mLCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-168h) After First Infusion of Isatuximab20200 ± 451019800 ± 459024300 ± 650026400 ± 6270
SecondaryPharmacokinetics (PK): Trough Plasma Concentrations (Ctrough) of Isatuximab

Ctrough was the plasma concentration of isatuximab observed just before treatment administration during repeated dosing.

Time frame:
Pre-infusion on Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 1 Day 15
Reported as:
Mean · mcg/mL
Pharmacokinetics (PK): Trough Plasma Concentrations (Ctrough) of Isatuximab
mcg/mLCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Cycle 1 Day 10 ± 00 ± 00 ± 00 ± 0
Cycle 1 Day 867.4 ± 20.071.0 ± 25.988.6 ± 21.899.9 ± 26.9
Cycle 1 Day 15153 ± 46.8121 ± 25.6176 ± 33.6231 ± 102
SecondaryPlasma Concentration of Atezolizumab
Time frame:
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1 and Cycle 16 Day 1

No measurements were reported for this outcome.

SecondaryBest Percent Change From Baseline in Tumor Burden

Best tumor burden change was defined as the best percent-change from baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.

Time frame:
From randomization until progression or death or study cut-off date whichever occurred first (maximum duration of exposure: up to 108 weeks)
Reported as:
Mean · percent change
Best Percent Change From Baseline in Tumor Burden
percent changeCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Best Percent Change From Baseline in Tumor Burden6.2 ± 31.5-3.4 ± 41.616.2 ± 51.1196.6 ± 347.5
SecondaryPercentage of Participants With Disease Control (DC) >=6 Months

DC: percentage of participants with complete response (CR), partial response (PR) \& stable disease (SD) rate. RANO criteria, CR: no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable/ reduced (red) T2/FLAIR signal, no new lesion (NL), no corticosteroid use (CU) \& stable/ red clinical status (CS); PR: \>=50% change in size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/ red CU \& stable/ improved CS (ICS). SD: \<50% reduction to \<25% increase (inc) size of T1-Gd+ disease, stable/red T2/FLAIR signal, no NL, stable/red CU \& stable/ICS. Progressive disease (PD): \>=25% inc size of T1-Gd+ disease/ inc T2/FLAIR signal/ presence of NL/ worsening CS. RECIST criteria: CR: Disappearance of target lesions. Reduction in short axis to \<10 mm of lymph nodes; PR: 30% decrease in sum of diameters of target lesions; PD: 20% inc in sum of diameters of target lesions; SD: Neither sufficient shrinkage from baseline study to qualify for PR nor sufficient inc to qualify for PD.

Time frame:
From the date of first response to disease progression or death, or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control (DC) >=6 Months
percentage of participantsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Percentage of Participants With Disease Control (DC) >=6 Months37.0 (21.7 to 54.7)41.4 (25.9 to 58.3)33.3 (15.6 to 55.4)3.0 (0.2 to 13.6)
SecondaryDuration of Response (DOR)

Time from date of 1st response until date of first documented recurrent/progressive disease (PD) or death whichever occurred 1st. In absence of disease progression or death before analysis cut-off date or date of initiation of further anticancer treatment, DOR was censored at date of last valid response. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1, CR: disappearance of all target lesions; PR: at least 30% decrease in sum of diameters of target lesions, PD: at least 20% increase in sum of diameters of target lesions. Per RANO criteria; CR: no change in size of T1-Gd+ disease, stable/reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable/improved status; PR: \>=50% change in size of T1-Gd+, stable/reduced T2/FLAIR signal, no new lesion, stable/reduced corticosteroid use, and stable/improved status. PD:\>=25% increase size of T1-Gd+/increased T2/FLAIR signal/presence of new lesion/worsening status.

Time frame:
From the date of first response until disease progression or death, or study cut-off date whichever occurred first (maximum duration of exposure: up to 108 weeks)
Reported as:
Mean · months
Duration of Response (DOR)
monthsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Duration of Response (DOR)7.5 ± 3.020.6 ± 7.310.4—
SecondaryProgression-free Survival (PFS)

PFS was defined as time (in months) from 1st study treatment administration to date of 1st documented radiographic progression or date of death from any cause, whichever was 1st. Participants who didn't experience progression or death before analysis cut-off date/date of initiation of new anticancer treatment, PFS was censored at date of last valid disease assessment not showing progression performed prior to initiation of further anticancer treatment or analysis cut-off date, whichever was 1st. RECIST 1.1 criteria was used for assessment in HCC/SCCHN/EOC Cohorts and RANO criteria for GBM Cohort. Per RECIST 1.1 criteria, PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study. Appearance of 1 or more new lesions was also considered progression. Per RANO criteria, PD: \>=25% increase in product of perpendicular diameters of any target lesion, or worsening neurologic status not explained by causes unrelated to tumor progression.

Time frame:
From date of first study treatment administration until disease progression or death or study cut-off whichever occurred first (maximum duration of exposure: up to 108 weeks)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Progression-free Survival (PFS)2.04 (1.840 to 4.008)2.10 (1.873 to 3.253)2.04 (1.906 to 3.943)1.28 (1.216 to 1.380)
SecondaryPercentage of Participants With Response as Per Response Assessment for Neuro-Oncology (RANO) Criteria: GBM Cohort

Response rate for participants with GBM was defined as percentage of participants with CR \& PR as best overall response (BOR), assessed by Investigators using RANO criteria. BOR was derived per RANO criteria using disease assessments performed from 1st dose of treatment through study excluding any assessments performed after cut-off date or following initiation of further anticancer treatment. Per RANO criteria; CR was defined as no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; PR was defined as \>=50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status. Progressive disease was defined as \>=25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.

Time frame:
From randomization until progression, or death, or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks for Cohort D-1)
Reported as:
Number · percentage of participants
Percentage of Participants With Response as Per Response Assessment for Neuro-Oncology (RANO) Criteria: GBM Cohort
percentage of participantsCohort D-1: GBM: Isatuximab + Atezolizumab
Percentage of Participants With Response as Per Response Assessment for Neuro-Oncology (RANO) Criteria: GBM Cohort0 (0.0 to 8.7)

Adverse events

Collected over From Baseline up to 30 days after last study treatment administration (maximum duration of exposure: 106 weeks for Cohort A, 108 weeks for Cohort B, 61 weeks for Cohort C and 54 weeks for Cohort D-1). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: HCC: Isatuximab + Atezolizumab4/27 (14.8%)12/27 (44.4%)25/27 (92.6%)
Cohort B: SCCHN: Isatuximab + Atezolizumab8/29 (27.6%)16/29 (55.2%)24/29 (82.8%)
Cohort C: EOC: Isatuximab + Atezolizumab3/18 (16.7%)8/18 (44.4%)18/18 (100%)
Cohort D-1: GBM: Isatuximab + Atezolizumab1/33 (3%)9/33 (27.3%)32/33 (97%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Disease ProgressionGeneral disorders3/274/293/181/33
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/270/292/181/33
Renal FailureRenal and urinary disorders2/270/290/180/33
Tumour HaemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/272/290/180/33
HemiparesisNervous system disorders0/270/290/182/33
Malignant AscitesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/270/291/180/33
Tumour Associated FeverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/270/291/180/33
AnaemiaBlood and lymphatic system disorders1/270/291/180/33
Decreased AppetiteMetabolism and nutrition disorders0/270/291/180/33
DehydrationMetabolism and nutrition disorders0/270/291/180/33
Most frequent other events
Showing 10 of 91
Most frequent other events
EventCohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + Atezolizumab
Infusion Related ReactionInjury, poisoning and procedural complications16/279/2914/1817/33
FatigueGeneral disorders5/276/297/187/33
HeadacheNervous system disorders3/274/291/1812/33
AstheniaGeneral disorders3/276/296/188/33
DiarrhoeaGastrointestinal disorders2/273/295/184/33
NauseaGastrointestinal disorders6/274/295/183/33
PyrexiaGeneral disorders3/277/293/181/33
Decreased AppetiteMetabolism and nutrition disorders6/272/293/181/33
DyspnoeaRespiratory, thoracic and mediastinal disorders3/270/294/181/33
Abdominal PainGastrointestinal disorders6/270/294/182/33

Baseline characteristics

Analysis was performed on all-treated population that included all the participants who signed the study informed consent and received at least 1 dose of the study treatments, either isatuximab or atezolizumab.

Age, Continuous
Age, Continuous(years)Cohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + AtezolizumabTotal
Mean62.8 ± 11.861.1 ± 9.156.3 ± 10.653.3 ± 13.358.3 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + AtezolizumabTotal
Female73181038
Male202602369
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: HCC: Isatuximab + AtezolizumabCohort B: SCCHN: Isatuximab + AtezolizumabCohort C: EOC: Isatuximab + AtezolizumabCohort D-1: GBM: Isatuximab + AtezolizumabTotal
American Indian or Alaska Native00000
Asian1194024
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1520132977
More than one race00000
Unknown or Not Reported10146
08

Study locations

26 sites
  • Investigational Site Number :8400004
    Santa Monica, California 90404, United States
  • Investigational Site Number :8400007
    Boston, Massachusetts 02115, United States
  • Investigational Site Number :8400002
    Houston, Texas 77030, United States
  • Investigational Site Number :0560001
    Bruxelles, 1200, Belgium
  • Investigational Site Number :0560002
    Gent, 9000, Belgium
  • Investigational Site Number :1240001
    Toronto, Ontario M5G 2M9, Canada
  • Investigational Site Number :2030001
    Brno, 65653, Czechia
  • Investigational Site Number :2030003
    Olomouc, 77900, Czechia
  • Investigational Site Number :2030002
    Praha 2, 12808, Czechia
  • Investigational Site Number :3800007
    Meldola, Forlì-Cesena 47014, Italy
  • Investigational Site Number :3800003
    Rozzano, Milano 20089, Italy
  • Investigational Site Number :3800009
    Milano, 20141, Italy
  • Investigational Site Number :3800004
    Padova, 35128, Italy
  • Investigational Site Number :5280001
    Rotterdam, 3015 CE, Netherlands
  • Investigational Site Number :7240001
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number :7240006
    Hospitalet de Llobregat, Castilla Y León 08908, Spain
  • Investigational Site Number :7240003
    Madrid / Madrid, Madrid, Comunidad De 28040, Spain
  • Investigational Site Number :7240004
    Madrid, Madrid, Comunidad De 28050, Spain
  • Investigational Site Number :7240008
    Pamplona, Navarra 31008, Spain
  • Investigational Site Number :7240007
    Madrid, 28041, Spain
  • Investigational Site Number :1580005
    Kaohsiung, 807, Taiwan
  • Investigational Site Number :1580002
    Tainan, 704, Taiwan
  • Investigational Site Number :1580001
    Taipei 100, Taiwan
  • Investigational Site Number :1580003
    Taipei, 104, Taiwan
  • Investigational Site Number :1580006
    Taipei, 112, Taiwan
  • Investigational Site Number :1580004
    Taipei, 114, Taiwan
09

References and documents

Publications

  • Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. ESMO Open. 2022 Oct;7(5):100562. doi: 10.1016/j.esmoop.2022.100562. Epub 2022 Aug 18. PubMed 35987165 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in May 2022, 45 months.

Results were first posted in Jun 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2018
First posted
Aug 20, 2018
StartActual
Aug 6, 2018
Primary completionActual
May 11, 2022
CompletionActual
May 11, 2022
Results first posted
Jun 8, 2023
Last update
Jul 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03637764
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Aug 6, 2018
Primary completion
May 11, 2022
Completion
May 11, 2022
Results posted
Jun 8, 2023
Last update
Jul 10, 2023

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion